NO133220B - - Google Patents
Download PDFInfo
- Publication number
- NO133220B NO133220B NO202271A NO202271A NO133220B NO 133220 B NO133220 B NO 133220B NO 202271 A NO202271 A NO 202271A NO 202271 A NO202271 A NO 202271A NO 133220 B NO133220 B NO 133220B
- Authority
- NO
- Norway
- Prior art keywords
- tablets
- release
- insoluble
- tablet
- digestive
- Prior art date
Links
- 239000013543 active substance Substances 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 11
- 230000001079 digestive effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002195 soluble material Substances 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 3
- 230000008855 peristalsis Effects 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 38
- 239000003814 drug Substances 0.000 description 22
- 229940079593 drug Drugs 0.000 description 14
- 239000008187 granular material Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000002198 insoluble material Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- -1 polyoxyethylene Polymers 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 235000019809 paraffin wax Nutrition 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000008991 intestinal motility Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960004482 quinidine sulfate Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920002433 Vinyl chloride-vinyl acetate copolymer Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE779170A SE353229B (enrdf_load_html_response) | 1970-06-04 | 1970-06-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO133220B true NO133220B (enrdf_load_html_response) | 1975-12-22 |
| NO133220C NO133220C (enrdf_load_html_response) | 1976-03-31 |
Family
ID=20272321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO202271A NO133220C (enrdf_load_html_response) | 1970-06-04 | 1971-05-28 |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS5443055B1 (enrdf_load_html_response) |
| CA (1) | CA951642A (enrdf_load_html_response) |
| DE (1) | DE2126810C3 (enrdf_load_html_response) |
| DK (1) | DK130387B (enrdf_load_html_response) |
| FI (1) | FI51900C (enrdf_load_html_response) |
| FR (1) | FR2104754B1 (enrdf_load_html_response) |
| GB (1) | GB1350255A (enrdf_load_html_response) |
| NL (1) | NL172824C (enrdf_load_html_response) |
| NO (1) | NO133220C (enrdf_load_html_response) |
| SE (1) | SE353229B (enrdf_load_html_response) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI63335B (fi) * | 1979-02-02 | 1983-02-28 | Orion Yhtymae Oy | Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne |
| HU190619B (en) * | 1983-11-11 | 1986-09-29 | Bezzegh,Denes,Hu | Process for producing tablets with controlled dissolution of active ingredients |
| DE3505433A1 (de) * | 1985-02-16 | 1986-08-21 | Basf Ag, 6700 Ludwigshafen | Direkttablettierhilfsmittel |
| FR2595945B1 (fr) * | 1986-03-19 | 1990-01-19 | Doms Laboratoires | Comprime-retard de theophylline a base de p.v.c., et son procede de preparation |
| SE8704097D0 (sv) * | 1987-10-22 | 1987-10-22 | Astra Ab | Oral formulation of buspirone and salts thereof |
| CN112891314A (zh) * | 2021-01-27 | 2021-06-04 | 陕西思瑰瑞食品科技有限公司 | 一种维生素c加硫酸亚铁缓控释片及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2987445A (en) * | 1958-10-10 | 1961-06-06 | Rohm & Haas | Drug composition |
-
1970
- 1970-06-04 SE SE779170A patent/SE353229B/xx unknown
-
1971
- 1971-05-26 DK DK254871A patent/DK130387B/da unknown
- 1971-05-28 GB GB1813671A patent/GB1350255A/en not_active Expired
- 1971-05-28 NO NO202271A patent/NO133220C/no unknown
- 1971-05-29 DE DE19712126810 patent/DE2126810C3/de not_active Expired
- 1971-06-03 FR FR7120259A patent/FR2104754B1/fr not_active Expired
- 1971-06-03 NL NL7107620A patent/NL172824C/xx not_active IP Right Cessation
- 1971-06-03 FI FI155871A patent/FI51900C/fi active
- 1971-06-04 CA CA114,804,A patent/CA951642A/en not_active Expired
- 1971-06-04 JP JP3868371A patent/JPS5443055B1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NL172824B (nl) | 1983-06-01 |
| DE2126810C3 (de) | 1980-11-20 |
| DK130387C (enrdf_load_html_response) | 1975-07-21 |
| FR2104754B1 (enrdf_load_html_response) | 1975-08-01 |
| FI51900B (enrdf_load_html_response) | 1977-01-31 |
| SE353229B (enrdf_load_html_response) | 1973-01-29 |
| NL172824C (nl) | 1983-11-01 |
| DK130387B (da) | 1975-02-17 |
| NO133220C (enrdf_load_html_response) | 1976-03-31 |
| DE2126810A1 (de) | 1971-12-16 |
| JPS5443055B1 (enrdf_load_html_response) | 1979-12-18 |
| GB1350255A (en) | 1974-04-18 |
| DE2126810B2 (de) | 1980-03-27 |
| CA951642A (en) | 1974-07-23 |
| NL7107620A (enrdf_load_html_response) | 1971-12-07 |
| FR2104754A1 (enrdf_load_html_response) | 1972-04-21 |
| FI51900C (fi) | 1977-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3108046A (en) | Method of preparing high dosage sustained release tablet and product of this method | |
| US3146169A (en) | Pharmaceutical formulations and their manufacture | |
| US2887438A (en) | Prolonged action tablets | |
| US3488418A (en) | Sustained relief analgesic composition | |
| DK170244B1 (da) | Indretning til kontrolleret afgivelse af aktive substanser samt fremgangsmåde til fremstilling af en sådan indretning | |
| De Haan et al. | Oral controlled release dosage forms. A review | |
| US3148124A (en) | Method of preparing sustained release pharmaceutical tablets | |
| KR880002673B1 (ko) | 진통 캡슐제와 그 제조방법 | |
| US3279998A (en) | Method of preparing sustained release tablets | |
| CN103417505B (zh) | 具有双相释药行为的石杉碱甲控释制剂及其制备方法 | |
| JPH01503070A (ja) | 薬剤持続放出マトリツクス及び方法 | |
| TW200529888A (en) | Particulates | |
| US3078216A (en) | Prolonged release oral pharmaceutical preparations | |
| NO309455B1 (no) | Filmbelagt tablett av paracetamol og domperidon | |
| CN104069502A (zh) | 复合骨架材料及其药物组合物 | |
| WO1992004013A1 (en) | Multiparticulate sustained release matrix system | |
| Deepika et al. | Matrix drug delivery system: a review | |
| NO133220B (enrdf_load_html_response) | ||
| JPH03145418A (ja) | 塩基性薬物塩酸塩の徐放性製剤 | |
| Otsuka et al. | Controlled drug release of highly water-soluble pentoxifylline from time-limit disintegration-type wax matrix tablets | |
| CN108289849A (zh) | 莫沙必利与雷贝拉唑的复合制剂 | |
| NO126201B (enrdf_load_html_response) | ||
| Pandit et al. | FORMULATION AND IN VITRO EVALUATION | |
| NO851083L (no) | Farmasoeytisk blanding inneholdende tetracyklin- eller doksycyklin-salter og fremgangsmaate til fremstilling av en slik blanding | |
| JPH10502937A (ja) | フシジン酸錠剤の製法 |